Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide composition as immunogen for treatment of allergy

A technology of conjugates and antigenic peptides, applied in the field of gEε heavy, can solve the problems of tedious synthesis

Inactive Publication Date: 2001-07-25
UNITED BIOMEDICAL INC
View PDF11 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this treatment model also has the following problems: Immunotherapy by anti-IgE is achieved by passive immunization, that is, by infusion of antibodies
These longer peptides are reliable but require tedious synthesis by a series of independent solid-phase peptide syntheses rather than rapid and simultaneous PEPSCAN synthesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] Design of identification peptides for potential effect sites on human IgE molecules

[0139] According to Helm et al. (1988) and Presta et al. (1994), the longer fragments covering the CH2 and CH3 regions of the human IgEε heavy chain participate in the binding of IgE to the FcεRI receptor, and the sites in the CH2 and CH3 regions of the human IgEε heavy chain are selected. Used for peptide simulation. Synthesize the sequences of these sites as target site peptides, by (1) linking them to a larger carrier protein such as KLH by chemical coupling, or (2) constructing that will contain mixed Th and Inv (SEQ ID NO: 13) Peptides are attached to the amino terminus of the target site, making them antigens. The specific sites in these regions were selected as peptides for cyclization based on Brookhaven's prediction of the three-dimensional model of exposed loops on the surface of human IgE (http:www.pdb.bnl.gov / pdb.bin / pdbids) . Specific cyclic constraints are introduced into the...

Embodiment 2

[0150] Identification of effect sites on human IgE molecules

[0151] Table 2 shows peptide conjugates with high affinity and cross-reactivity to human IgE (such as their respective antisera with anti-IgE titers higher than log 10 = 3) in the screening of IgE-CH3 region antigen peptides. The guinea pig hyperimmune serum was prepared as described above. The guinea pig IgG antibody was purified from hyperimmune serum by protein A affinity chromatography, and the ability of anti-IgE to inhibit the colonization of human basophils through allergen-specific IgE was determined by functional analysis. The analytical endpoint is expressed as the percentage inhibition of histamine release by IgE-street.

[0152] The guinea pig IgG antibody was purified from serum by protein A affinity chromatography (ImmunoPure(R) Immobilized Recomb(R) Protein A, Pierce), and the eluted antibody was prepared into 25mM PIPES buffer, 0.15M NaCl, a standard concentration of 8mg / ml in pH 7.2. A control antibody...

Embodiment 3

[0160] Isotype's immunosuppressive specificity and potential

[0161] The specificity comparison of the polyclonal antibody induced by the active immune response of SEQ ID NOS: 14 and 15 to IgE and IgG was examined. The anti-15b guinea pig antibody prepared from the 12-week blood sample described in Example 2 was compared in parallel for the cross-reactivity of IgE and IgG through the IgE ELISA described in Example 1 and similar IgG ELISA. For IgE ELISA, plates were coated with 5 μg / ml human IgE myeloma. For IgG ELISA, plates were coated with 5 μg / ml purified human IgG (Sigma reagent grade human IgG). The reactivity of purified guinea pig anti-15b at concentrations of 0.5 and 0.1 μg / ml was tested in the above two ELISAs. The results were compared with antibodies purified from control guinea pig serum and "no antibody" controls. When the concentration of anti-15b antibody is 0.5μg / ml, the A in IgE 490 The value is 1.126, which is 0.344 at a concentration of 0.1 μg / ml. Anti-15b anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides peptides comprising a sequence homologous to a portion of the third constant domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical compositions, to provide an immunotherapy for IgE-mediated allergic diseases.

Description

Invention field [0001] The present invention relates to the application of a peptide binding composition as an immunogen. Each peptide conjugate contained therein includes a third constant region located in the heavy chain of IgEε (CH 3 ), the target antigen site is covalently connected (1) a carrier protein by chemical coupling, or (2) a helper T cell epitope by chemical coupling or by direct synthesis and Other immunostimulatory sequences are used to treat allergies. [0002] More specifically, the present invention relates to the application of the peptide binding composition as an immunogen to induce the production of high-titer polyclonal antibodies specific to the target effector on the heavy chain domain of IgEε in mammals including humans, and also relates to the composition As a drug application, it provides immunotherapy for IgE-mediated allergies. Background of the invention [0003] In the immune system of humans and other mammals, IgE mediates type I hypersensitivity...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/095A61K39/00A61K39/385A61K39/44A61P37/08C07K16/00C07K16/42C07K19/00
CPCA61K39/0008C07K2316/52A61K2039/6081C07K16/4291A61K39/385C07K16/00C07K2317/52A61K38/00A61K2039/6075A61P37/08
Inventor 王长怡阿兰·M·威尔菲尔德
Owner UNITED BIOMEDICAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com